1. Home page
  2. Contents
  3. Statural Growth
  1. Home page
  2. Contents
  3. Statural Growth
Medical and paramedical

Statural Growth

The definitive height of people with trisomy 21 is a source of concern for their parents and a universal question. Short definitive height, achieved 2 years earlier than in the neurotypical population, is characteristic of patients with trisomy 21. Although this statural growth retardation is constitutional, it can be aggravated by many comorbidities. To preserve the full growth potential of these children, their height and cranial perimeter growth must be carefully monitored on specific curves. This is especially important since, apart from in the case of a rare associated somatotrophic deficit, growth hormone treatment does not provide any significant benefits for children with trisomy 21.

Find more information on the general progression, differences by country, and critical growth periods of patients with trisomy 21 in this video and accompanying technical sheet by Dr. Hervé Walti, a pediatrician at the Jérôme Lejeune Institute.

See below for the presentation accompanying this video on “statural growth”

Please wait while flipbook is loading. For more related info, FAQs and issues please refer to DearFlip WordPress Flipbook Plugin Help documentation.

  • Annerén G, Tuvemo T, Carlsson-Skwirut C, Lönnerholm T, Bang P, Sara VR, Gustafsson J. Growth hormone treatment in young children with Down’s syndrome: effects on growth and psychomotor development. Arch Dis Child. 1999 Apr;80(4):334-8. doi: 10.1136/adc.80.4.334. PMID: 10086938; PMCID: PMC1717881.
  • Le guide d’utilisation des nouvelles courbes de croissance de l’OMS à l’intention du professionnel de la santé Paediatr Child Health Vol 15 No 2 February 2010
  • Mircher C, Briceño LG, Toulas J, Conte M, Tanguy ML, Cieuta-Walti C, Rethore MO, Ravel A. Growth curves for French people with Down syndrome from birth to 20 years of age. Am J Med Genet A. 2018 Dec;176(12):2685-2694. doi: 10.1002/ajmg.a.40639. Epub 2018 Dec 20. PMID: 30569664.
  • Myrelid Å, Bergman S, Elfvik Strömberg M, Jonsson B, Nyberg F, Gustafsson J, Annerén G. Late effects of early growth hormone treatment in Down syndrome. Acta Paediatr. 2010 May;99(5):763-769. doi: 10.1111/j.1651-2227.2009.01679.x. Epub 2010 Jan 25. PMID: 20105143.
  • Zemel BS, Pipan M, Stallings VA, Hall W, Schadt K, Freedman DS, Thorpe P. Growth charts for children with Down syndrome in the United States. Pediatrics. 2015 Nov 1;136(5):e1204-11
  • https://www.cdc.gov/ncbddd/birthdefects/downsyndrome/growth-charts.html

Similar contents

See all content

Sign Up

Sign up to receive our newsletter and stay informed of new content!

        Institut Jérôme Lejeune
        37 rue des Volontaires
        75015 PARIS

        Institut Jérôme Lejeune
        37 rue des Volontaires 75015 PARIS

        Follow the Jérôme Lejeune Institute’s
        news on our social media accounts

        Follow the Jérôme Lejeune Institute’s news on our social media accounts

         Votre inscription a bien été prise en compte